Our top pick for
AxoGen Inc is a medical devices business based in the US. AxoGen shares (AXGN) are listed on the NASDAQ and all prices are listed in US Dollars. AxoGen employs 346 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$14.61|
|52-week range||$11.54 - $23.49|
|50-day moving average||$15.94|
|200-day moving average||$18.73|
|Wall St. target price||$27.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.54|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-10)||N/A|
|1 month (2021-09-21)||-6.82%|
|3 months (2021-07-21)||-27.57%|
|6 months (2021-04-21)||-24.26%|
|1 year (2020-10-21)||11.61%|
|2 years (2019-10-21)||14.77%|
|3 years (2018-10-19)||33.51|
|5 years (2016-10-21)||63.24%|
|Revenue TTM||$130.5 million|
|Gross profit TTM||$90.7 million|
|Return on assets TTM||-6.5%|
|Return on equity TTM||-18.49%|
|Market capitalisation||$563.8 million|
TTM: trailing 12 months
There are currently 945,101 AxoGen shares held short by investors – that's known as AxoGen's "short interest". This figure is 9.7% down from 1.0 million last month.
There are a few different ways that this level of interest in shorting AxoGen shares can be evaluated.
AxoGen's "short interest ratio" (SIR) is the quantity of AxoGen shares currently shorted divided by the average quantity of AxoGen shares traded daily (recently around 120702.55427842). AxoGen's SIR currently stands at 7.83. In other words for every 100,000 AxoGen shares traded daily on the market, roughly 7830 shares are currently held short.
However AxoGen's short interest can also be evaluated against the total number of AxoGen shares, or, against the total number of tradable AxoGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AxoGen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AxoGen shares in existence, roughly 20 shares are currently held short) or 0.0276% of the tradable shares (for every 100,000 tradable AxoGen shares, roughly 28 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AxoGen.
Find out more about how you can short AxoGen stock.
We're not expecting AxoGen to pay a dividend over the next 12 months.
AxoGen's shares were split on a 105:100 basis on 10 July 1994. So if you had owned 100 shares the day before before the split, the next day you'd have owned 105 shares. This wouldn't directly have changed the overall worth of your AxoGen shares – just the quantity. However, indirectly, the new 4.8% lower share price could have impacted the market appetite for AxoGen shares which in turn could have impacted AxoGen's share price.
Over the last 12 months, AxoGen's shares have ranged in value from as little as $11.54 up to $23.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AxoGen's is 0.7534. This would suggest that AxoGen's shares are less volatile than average (for this exchange).
AxoGen, Inc. , together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.